Mistletoe therapy, derived from the Viscum album plant, has been gaining increasing attention as a complementary treatment for breast cancer. ABNOBA GmbH, a German-based research-driven pharmaceutical company, is at the forefront of this innovative approach, offering standardized mistletoe extracts that are now being introduced in India through ABNOBA India.
Used primarily in integrative oncology, mistletoe therapy aims to support the body’s immune response and improve the quality of life in cancer patients. In breast cancer treatment, it is often used alongside conventional methods such as chemotherapy, radiation, and surgery. Patients report reduced side effects, better tolerance to chemo, and improved energy levels and emotional well-being.
Mistletoe extract contains active compounds like lectins and viscotoxins, which stimulate the immune system and may slow the growth of cancer cells. Clinical studies in Europe have shown promising results, particularly in enhancing patient resilience and prolonging survival in some cases.
ABNOBA’s commitment to research ensures that their mistletoe products are highly purified, safe, and effective. In India, where cancer rates are steadily rising, ABNOBA India aims to make mistletoe therapy more accessible to patients seeking integrative and supportive care.
While mistletoe therapy is not a cure, it offers a valuable supportive role in breast cancer treatment. Patients should always consult their oncologist before starting any complementary therapy. As awareness grows, mistletoe therapy stands as a hopeful, holistic option in the journey of healing and recovery for breast cancer patients.
